Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Raymond Douglas, MD, PhD
Healthcare Professional Director
Orbital and Thyroid Eye Disease Program
Cedars-Sinai Medical Center
8700 Beverly Blvd
Los Angeles, California, United States
Dr. Raymond Douglas is the Director of the Orbital and Thyroid Eye Disease Program and Professor of Ophthalmology at the prestigious Cedars-Sinai Medical Center in Los Angeles. He is also an experienced and board certified oculoplastic surgeon in Beverly Hills, California. Besides this he has held positions at the University of California Los Angeles (UCLA) School of Medicine, Harbor-UCLA Medical Center, Greater Los Angeles Veterans Hospital, Veterans Administration Ann Arbor Healthcare System, and the University of Michigan Kellogg Eye Center.
After graduating with academic distinction from the University of Pennsylvania, Dr. Douglas completed an opthalmology residency at the University of Pennsylvania. He then completed a sub-specialized fellowship in orbital facial plastic and reconstructive surgery at the University of California Los Angeles Jules Stein Eye Institute.
Patients with thyroid eye disease, previous unsuccessful surgery (blepharoplasty), cancers of the eyelids and face, and trauma-induced injuries all seek Dr. Douglas’ expert care. His expertise in treating thyroid-associated eye diseases and cosmetic and reconstructive surgeries has made him a highly respected and sought-after physician. In addition to his customized approach to patient care, Dr. Douglas is widely recognized for his ground-breaking research on treatments for Graves’ or thyroid-associated orbitopathy.
Representative Publications:
Risk Factors for Developing Thyroid-Associated Ophthalmopathy Among Individuals With Graves Disease
Pharmacological Treatments for Thyroid Eye Disease
Reactivation of Thyroid-Associated Orbitopathy After Cataract Surgery
Related Content
-
Eyes on Graves’: LaQuilla’s Storyhttps://www.youtube.com/watch?v=98tJEN1C...
-
High Serum Cholesterol is a Novel Risk Factor for Graves’ Orbitopathy: Results of a Cross-Sectional StudyBackground: Limited data suggest that t...
-
Remission After Potassium Iodide Therapy in Patients With Graves’ Hyperthyroidism Exhibiting Thionamide-Associ...Context: Thionamides have various side ...
-
Ken Kazahaya, MD, MBA, FACSKen Kazahaya is Associate Director of th...
-
Mycophenolate Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-Severe Graves’ Or...Background: European guidelines recomme...
-
James A. Garrity, MDDr. James Garrity is an Emeritus Whitney...
-
Meeting of Dermatologic and Ophthalmic Drugs Advisory Committee AnnouncementThe committee will discuss biologics lic...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.